NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve

NeoGenomics came into this print as an expensive growth story in cancer diagnostics, with a rich P/S multiple and a long stretch of losses. The stock jumped about 14% to US$15.27 today, which indicates investors liked what they saw. The key focus is margin and profit repair. NeoGenomics moved from a loss in Q1 to a modest profit in Q2 and lifted adjusted EBITDA, helped by higher average price per test and its Lab of the Future efficiency work. The rest of the earnings detail supports that shift.

Is NeoGenomics’ premium 2.6x P/S multiple justified by this early profit swing, or does it stretch the story too far? Compare the stock’s pricing against its fundamentals in the valuation analysis for NeoGenomics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$201.7m vs. US$181.3m (up about 11%)
• Net Income, Q2 2026 vs. Q2 2025: Profit of US$2.2m vs. loss of US$45.1m (swing to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.02 vs. loss of US$0.35 per share (swing to earnings per share)
• Adjusted Gross Margin, Q2 2026 vs. Q2 2025: 48.1% vs. about 45.5% (improved by 260 basis points, or 2.6 percentage points)

Prefer clean visual charts instead of another dense wall of earnings commentary and ratios? Explore NeoGenomics’ full financial picture, with a focus on its earnings profile and profitability trends, in the company report for NeoGenomics.

NeoGenomics Bull Case Hangs On Execution Milestones

Bulls argue NeoGenomics can shift from a volume story to a higher value oncology platform, with NGS and operational upgrades driving better margins and cash generation. Q2 gives real evidence for that view. Clinical revenue grew with average price per test up 12%, while NGS revenue rose 26% and is now about one third of clinical revenue. That supports the idea of a richer test mix rather than just more low margin volume.

The efficiency narrative also shows up in the numbers. Adjusted gross margin improved to 48.1% and adjusted EBITDA increased to US$14.4m, helped by the Lab of the Future automation work and better managed care pricing. Management lifted full year revenue and adjusted EBITDA guidance and now expects full year gross margin expansion of about 100 to 150 basis points. Those are concrete milestones for a thesis that hinges on operational leverage rather than pure top line growth.

Compare whether NeoGenomics’ margin gains and higher value test mix line up with institutional expectations. See the consensus price target analysis for NeoGenomics

NeoGenomics Bear Case: Pharma Weakness Still Unfixed

Bears worry NeoGenomics is over earning on clinical mix while its pharma services business quietly erodes and delays the path to a balanced, durable model. Q2 does not put that concern to bed. Nonclinical revenue was US$14.5m and fell 15% year on year, with pharma services down 26%. Management now expects nonclinical revenue to be down high single digits for 2026. That is a clear miss versus any thesis that pharma would stabilize quickly.

Execution risk around big spending programs is another key bearish theme. Lab of the Future is helping adjusted gross margin and EBITDA today, yet the company is still absorbing CapEx, a US$10m DOJ settlement payment and the complexity of a US$316m convertible refinancing. The move to a profit and higher guidance challenges fears of no operating leverage, but the structural concern about underutilized pharma capacity and a heavier balance sheet is not fully resolved.

After a swing from heavy losses to profit, are NeoGenomics’ pharma headwinds and refinancing costs just early warning signs? Review the full risk analysis for NeoGenomics which shows 1 important warning sign

Stay Ahead With Simply Wall St

If NeoGenomics’ move from heavy losses to a Q2 profit has your attention, register for free with Simply Wall St and add it to your Watchlist to keep an eye on price versus fair value and wait for a setup that fits your plan. Once you own NeoGenomics or other stocks, use the Portfolio Command Center to cut through noise and focus on the updates that actually matter for your holdings. For a broader perspective on NeoGenomics and similar stories, tap into the collective insight of thousands of investors through the Community. That way you surface potential catalysts and risks earlier and give yourself a better chance of staying ahead of the market.

Curious About Alternatives Beyond NeoGenomics

Fresh stock ideas can start moving fast once the crowd catches on. Scan for potential breakouts while the data is still under the radar for now and act now.

• Spot companies with strong balance sheets before momentum really gets flying by running a focused hunt through the list of solid balance sheet and fundamentals stocks (48 results).
• Explore early growth stories connected to AI by checking curated opportunities inside the 64 profitable AI stocks that aren't just burning cash while they are still under followed.
• Find potential income-oriented companies with steady cash flows by scanning the hand picked lineup in the 9 dividend fortresses before yields change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com